In the Boardroom
Refine Search
Biotechnology
Dutch rare diseases biotech firm ProQR Therapeutics today announced the appointment of Dr Cristina Lopez Lopez as chief medical officer (CMO). 14 April 2025
Biotechnology
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Biotechnology
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Biotechnology
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
Biotechnology
China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones. 7 April 2025
Biotechnology
Italy-based Angelini Ventures, the corporate venture arm of Angelini Industries, has named Regina Hodits as managing director as it looks to scale its biotech investment activities across Europe and North America. 7 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Biotechnology
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Biotechnology
US biotech Inhibrx Biosciences has announced a leadership shake-up following the departure of co-founder Brendan Eckelman, who is leaving to establish a new privately-held biotech company. 2 April 2025
Pharmaceutical
French drugmaker Sanofi has appointed Chris Corsico as its new global head of development, according to an internal company communication obtained by The Pharma Letter. 2 April 2025
Biotechnology
French biotech Transgene has named Simone Steiner as its new chief technical officer, in a move aimed at advancing the development and production of its virus-based immunotherapies. 2 April 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine Wilke as chief medical officer (CMO), taking over from interim CMO Heike Oberwittler. 1 April 2025
Biotechnology
Olga Uspenskaya-Cado has been named chief medical officer (CMO) of VectorY Therapeutics, a privately-held Dutch biotech advancing vectorized antibody therapies for neurodegenerative diseases. 1 April 2025
Pharmaceutical
Nuage Therapeutics, a Barcelona-based firm specializing in precision therapies for cancer, has appointed Stuart Hughes as chief executive and Vanessa Malier as chair of the board. Mr Hughes succeeds founding CEO Judit Anido, who will assist during the leadership transition. 1 April 2025
Pharmaceutical
Japanese drugmaker Nxera Pharma today announced two new appointments to its leadership team: Kiyoshi Kaneko, is appointed as chief commercial officer (CCO), and Mariko Nakafuji is promoted into the role of chief legal officer (CLO). 1 April 2025
Biotechnology
German contract development and manufacturing specialist ProBioGen has named Alfred Merz as its new chief executive. He had been serving as chief operating officer and interim chief executive since joining the company in 2024 from Bayer (BAYN: DE).
Mr Merz brings more than 30 years of experience across major pharmaceutical companies, including Bayer and Novartis (NOVN: VX). At Bayer, he was senior vice president and head of product supply for medical devices. 31 March 2025
Biotechnology
Asgard Therapeutics, a privately-held biotech working in in vivo direct cell reprogramming for cancer immunotherapy, has named experienced immunology drug development specialist Shane Olwill its chief development officer (CDO). 26 March 2025
Pharmaceutical
Norwegian bladder cancer specialist Photocure has appointed Jane Healy as vice president and general manager EMEA. 26 March 2025
Biotechnology
Dutch rare diseases biotech firm ProQR Therapeutics today announced the appointment of Dr Cristina Lopez Lopez as chief medical officer (CMO). 14 April 2025
Biotechnology
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Biotechnology
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Biotechnology
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
Biotechnology
China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones. 7 April 2025
Biotechnology
Italy-based Angelini Ventures, the corporate venture arm of Angelini Industries, has named Regina Hodits as managing director as it looks to scale its biotech investment activities across Europe and North America. 7 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Biotechnology
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Biotechnology
US biotech Inhibrx Biosciences has announced a leadership shake-up following the departure of co-founder Brendan Eckelman, who is leaving to establish a new privately-held biotech company. 2 April 2025
Pharmaceutical
French drugmaker Sanofi has appointed Chris Corsico as its new global head of development, according to an internal company communication obtained by The Pharma Letter. 2 April 2025
Biotechnology
French biotech Transgene has named Simone Steiner as its new chief technical officer, in a move aimed at advancing the development and production of its virus-based immunotherapies. 2 April 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine Wilke as chief medical officer (CMO), taking over from interim CMO Heike Oberwittler. 1 April 2025
Biotechnology
Olga Uspenskaya-Cado has been named chief medical officer (CMO) of VectorY Therapeutics, a privately-held Dutch biotech advancing vectorized antibody therapies for neurodegenerative diseases. 1 April 2025
Pharmaceutical
Nuage Therapeutics, a Barcelona-based firm specializing in precision therapies for cancer, has appointed Stuart Hughes as chief executive and Vanessa Malier as chair of the board. Mr Hughes succeeds founding CEO Judit Anido, who will assist during the leadership transition. 1 April 2025
Pharmaceutical
Japanese drugmaker Nxera Pharma today announced two new appointments to its leadership team: Kiyoshi Kaneko, is appointed as chief commercial officer (CCO), and Mariko Nakafuji is promoted into the role of chief legal officer (CLO). 1 April 2025
Biotechnology
German contract development and manufacturing specialist ProBioGen has named Alfred Merz as its new chief executive. He had been serving as chief operating officer and interim chief executive since joining the company in 2024 from Bayer (BAYN: DE).
Mr Merz brings more than 30 years of experience across major pharmaceutical companies, including Bayer and Novartis (NOVN: VX). At Bayer, he was senior vice president and head of product supply for medical devices. 31 March 2025
Biotechnology
Asgard Therapeutics, a privately-held biotech working in in vivo direct cell reprogramming for cancer immunotherapy, has named experienced immunology drug development specialist Shane Olwill its chief development officer (CDO). 26 March 2025
Pharmaceutical
Norwegian bladder cancer specialist Photocure has appointed Jane Healy as vice president and general manager EMEA. 26 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze